How do ALK-inhibitors work in ALK-positive lung cancer?

Each year lung cancer causes over 1.59 million deaths worldwide, more than any other cancer. Approximately 85% of lung cancer cases are a type of lung cancer called non-small cell lung cancer, and of these 5% are anaplastic lymphoma kinase (ALK)-positive. This type of lung cancer can be effectively targeted by a type of drug called an ALK-inhibitor, but how do they work?

Subscribe to our YouTube channel now: https://www.youtube.com/user/r....oche?sub_confirmatio

Get in touch with us:

https://www.roche.com/
https://www.facebook.com/RocheCareers
https://www.linkedin.com/company/roche
https://twitter.com/roche

Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

For more information and insights visit: https://www.roche.com/